Freund M, Giller S, Hinrichs F, Baars A, Meran J, Körfer A, Link H, Poliwoda H
Department of Haematology and Oncology, Hannover Medical School, Federal Republic of Germany.
J Cancer Res Clin Oncol. 1991;117(5):489-92. doi: 10.1007/BF01612772.
Twenty-two patients with acute myeloid leukemia (AML), having a median age of 48.3 years (range 26-70; 10 male, 12 female), were treated with 4'-(9-acridinylamino) methanesulphon-m-anisidide (m-AMSA) 100 mg/m2 and cytosine arabinoside (AraC) 2 x 1000 mg/m2i.v. on days 1-5. There were 2M1,8 M2, 9 M4, 2M4 Eo, and 1 M5a. Of these, 12 achieved a complete remission, 3 a partial remission and 6 did not respond. The median remission duration was 9.0 months and the median overall survival 8.1 months. Side-effects of induction consisted mainly of haematological toxicity and infections with a median duration of WHO-grade-4 granulopenia and thrombopenia of 20 and 28 days respectively. Organ toxicity was mild with mucositis and cutaneous and liver toxicity being experienced by only a few patients. There was one treatment-related death. Five-day m-AMSA and intermediate-dose AraC is an easy-to-handle condensed treatment schedule with tolerable toxicity. Its effectiveness in relapsed and refractory AML is comparable to combinations of high-dose AraC with m-AMSA, anthracyclines or etoposide.
22例急性髓系白血病（AML）患者，中位年龄48.3岁（范围26 - 70岁；男性10例，女性12例），接受4' -（9 - 吖啶基氨基）甲磺基 - m - 茴香胺（m - AMSA）100 mg/m²及阿糖胞苷（AraC）2×1000 mg/m²静脉注射，于第1 - 5天给药。其中有2例M1、8例M2、9例M4、2例M4 Eo和1例M5a。这些患者中，12例达到完全缓解，3例部分缓解，6例无反应。中位缓解持续时间为9.0个月，中位总生存期为8.1个月。诱导治疗的副作用主要为血液学毒性和感染，WHO 4级粒细胞减少和血小板减少的中位持续时间分别为20天和28天。器官毒性较轻，仅有少数患者出现黏膜炎、皮肤毒性和肝毒性。有1例与治疗相关的死亡。5天的m - AMSA和中剂量AraC是一种易于操作的简化治疗方案，毒性可耐受。其对复发和难治性AML的疗效与高剂量AraC联合m - AMSA、蒽环类药物或依托泊苷的联合方案相当。
